Patient no. | Age | Sex | Primary site | Histopathology | Accumulated dose of prior RT (Gy) | Recurrent stage | Tumor diameter (cm) |
---|---|---|---|---|---|---|---|
1 | 68 | M | Hypopharynx | SCC | 136.4 in 2 courses | T1N2a | 4 |
2 | 67 | M | Tongue | SCC | 66 | T2N2a | 9.5 |
3 | 49 | F | Nasal cavity | Sinonasal carcinoma | 120 in 2 courses | T4N0 | 5 |
4 | 71 | M | Gingiva | SCC | 66 | T4N0 | 7.5 |
5 | 46 | M | Nasopharynx | Undifferentiated ca | 136 in 2 courses | T4N0 | 3.9 |
6 | 58 | F | Nasopharynx | Non-keratinizing ca | 122 in 2 courses | T3N0 | 2.5 |
7 | 57 | M | Tongue | SCC | 70 | T3N0 | 4.5 |
8 | 52 | M | Tongue | SCC | 70 | T4aN0 | 5.3 |
9 | 54 | M | Maxillary sinus | SCC | 70 | T3N0 | 8.9 |
10 | 54 | M | Tongue | SCC | 63 | T0N2b | 6.0 |
11 | 48 | M | Tongue | Spindle cell sarcoma | 107 in 2 courses | T4bN0 | 6.0 |
12 | 74 | M | Maxillary sinus | SCC | 105 in 2 courses | T2N0 | 3.5 |
13 | 51 | M | Parotid gland | Adenocarcinoma | 136 in 2 courses | T4N0 | 5.8 |
14 | 56 | M | Buccal mucosa | SCC | 125.9 in 2 courses | T1N0 | 0.9 |
15 | 40 | M | Hypopharynx | SCC | 95 in 2 courses | T3N0 | 4.7 |
16 | 59 | M | Nasopharynx | Non-keratinizing ca | 136 in 2 courses | T3N0 | 3.9 |
17 | 62 | M | Buccal mucosa | SCC | 64 | T4aN0 | 6.4 |